{"id":"W2958944135","doi":"10.1200/jco.2019.37.8_suppl.100","title":"CheckMate 384: Phase IIIb/IV trial of nivolumab (nivo) 480 mg Q4W versus 240 mg Q2W after ≤ 12 months of nivo in previously treated advanced NSCLC.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Southlake Regional Health Center","funders":"","keywords":"Medicine; Dosing; Interim analysis; Nivolumab; Internal medicine; Safety profile; Pharmacokinetics; Randomized controlled trial; Gastroenterology; Oncology; Adverse effect; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000991753,0.00120205,0.001133541,0.0003211195,0.0002771206,0.0008367326,0.0009378068,0.001111532,0.009245618],"category_scores_gemma":[0.0007577509,0.0004163472,0.001011091,0.0002250362,0.0005916269,0.0005960503,0.0003440797,0.002462315,0.001011194],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001280728,"about_ca_system_score_gemma":0.001323345,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001486744,"about_ca_topic_score_gemma":0.0046003,"domain_scores_codex":[0.9997975,0.00008671342,0.00000996949,0.00003900936,0.00002088096,0.00004594528],"domain_scores_gemma":[0.9996151,0.00005610017,0.0000941907,0.00002798194,0.00001893775,0.0001877099],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9202548,0.01866977,0.002254982,0.000671652,0.0006451313,0.00008207574,0.00007864722,0.001408309,0.0181256,0.0002611971,0.003978826,0.03356907],"study_design_scores_gemma":[0.8132815,0.1730577,0.006443699,0.00003798919,0.0004524819,0.00009276289,0.000029361,0.001226632,0.002320684,0.0002033305,0.002829154,0.00002459921],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893165,0.001241906,0.0003651128,0.0003989561,0.0002206441,0.003138416,0.002244825,0.0001489851,0.002924705],"genre_scores_gemma":[0.9842164,0.0008035241,0.001127118,0.000806609,0.0001538997,0.003289284,0.00330821,0.00002974008,0.006265197],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009245618,"threshold_uncertainty_score":0.03092963,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07353088413689789,"score_gpt":0.4558853785881979,"score_spread":0.3823544944513,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}